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Abstract
Background: Alternative models for sustainable antiretroviral treatment (ART) delivery are necessary to meet the
increasing demand to maintain population-wide ART for all people living with HIV (PLHIV) in sub-Saharan Africa. We
undertook a review of published literature comparing health facility-based care (HFBC) with non-health facility
based care (nHFBC) models of ART delivery in terms of health outcomes; viral suppression, loss to follow-up,
retention and mortality.
Methods: We conducted a systematic search of Medline, Embase and Global Health databases from 2010 onwards.
UNAIDS reports, WHO guidelines and abstracts from conferences were reviewed. All studies measuring at least one
of the following outcomes, viral load suppression, loss-to-follow-up (LTFU) and mortality were included. Data were
extracted, and a descriptive analysis was performed. Risk of bias assessment was done for all studies. Pooled
estimates of the risk difference (for viral suppression) and hazard ratio (for mortality) were made using random-
effects meta-analysis.
Results: Of 3082 non-duplicate records, 193 were eligible for full text screening of which 21 published papers met
the criteria for inclusion. The pooled risk difference of viral load suppression amongst 4 RCTs showed no evidence
of a difference in viral suppression (VS) between nHFBC and HFBC with an overall estimated risk difference of 1%
[95% CI -1, 4%]. The pooled hazard ratio of mortality amongst 2 RCTs and 4 observational cohort studies showed
no evidence of a difference in mortality between nHFBC and HFBC with an overall estimated hazard ratio of 1.01
[95% CI 0.88, 1.16]. Fifteen studies contained data on LTFU and 13 studies on retention. Although no formal
quantitative analysis was performed on these outcomes due to the very different definitions between papers, it was
observed that the outcomes appeared similar between HFBC and nHFBC.
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Conclusions: Review of current literature demonstrates comparable outcomes for nHFBC compared to HFBC ART
delivery programmes in terms of viral suppression, retention and mortality.
PROSPERO number: CRD42018088194.
Keywords: Human immunodeficiency virus, Antiretroviral therapy, Sub-Saharan Africa, Community-based delivery
Background
There are an estimated 37.9 million people living with
human immunodeficiency virus (HIV) globally and 32
million people have died from AIDS-related illnesses
since the start of the epidemic [1]. The HIV epidemic
has disproportionately affected Africa, particularly
sub-Saharan Africa (SSA) which has the largest bur-
den of the disease. Although the region accounts for
approximately 6.2% of the world’s total population, it
is home to over 50% (20.6 million) of the total num-
ber of PLHIV globally, with over 800,000 new infec-
tions recorded in 2018 [2].
Antiretroviral therapy (ART) controls viral replica-
tion to below the limit of detection and in doing so,
improves survival [3, 4] and limits the risk of on-
ward viral transmission [5, 6], but requires daily life-
long adherence to oral medication. Stopping ART
invariably leads to rapid viral recrudescence and re-
versal of its beneficial effects [7]. In order to signifi-
cantly reduce the number of new HIV infections
globally, UNAIDS in 2014 set coverage targets by
2020 for the three key indicators; knowledge of HIV
status for 90% of people living with HIV (PLHIV),
ART access for at least 90% of all PLHIV and viral
suppression for at least 90% of all of those living
with HIV on ART; the “90–90-90 targets” with the
aspiration to end the HIV epidemic by 2030 [8]. Fol-
lowing the World Health Organization (WHO) 2015
recommendation of lifelong ART for all PLHIV re-
gardless of CD4 count and clinical staging [9], there
has been substantial progress in scaling up ART pro-
grams; and by mid-2018, 84% of low- and middle-
income countries had adopted these guidelines [10,
11] to provide universal treatment to all PLHIV.
Despite the high HIV burden, SSA has made tre-
mendous progress in treatment coverage and by
2018, 85% of PLHIV were aware of their status and
67% (13.8 million) were on treatment [12, 13].
Maintaining this unprecedented scale-up of ART services
poses a challenge in high HIV burden resource limited
settings, especially in SSA where healthcare facilities are
overburdened with long waiting times, inadequate and
overburdened human resources, transportation costs, con-
gestion and long waiting times at the health facility-based
care (HFBC) [14, 15], leading to poor retention in care and
adherence. Recent data from sub-Saharan Africa (SSA)
shows 5- year retention on ART is close to 60% [16–21].
Decentralizing ART provision services outside of the
HFBC into the communities holds the promise of im-
proving the continuum of care and facilitating access to
treatment. Various models of non-health facility-based
care (nHFBC) [22] have been piloted and implemented
in high burden low resource settings and are now being
increasingly recognised as safe and effective alternatives
to the current standard model of health facility-based
care in SSA [23, 24]. These include; healthcare worker-
managed groups (adherence clubs); client managed
group models (community adherence groups (CAGs));
and out-of-facility individual models (community-based
distribution points (CBDPs) and home-based delivery).
Adherence clubs consists of a group of 15–30 stable
PLHIV who meet up at a venue within or outside the
HFBC space, once every 2–3 months where they receive
their adherence support and pre-packed medications by
a trained lay worker or healthcare worker. Club mem-
bers are seen once or twice-yearly at the clinic for rou-
tine clinical review and laboratory tests [25–29]. CAGs,
originally developed by Médecins Sans Frontiéres (MSF)
in Tete, Mozambique, also target stable patients who re-
ceive ART refills and adherence support in a group,
where each member of the group takes turns collecting
ART for all group members. Each group is composed of
approximately six patients who meet up every 2–3
months, and each member has their routine clinical visit
once or twice-yearly [26, 30–32]. Out-of-facility models
vary according to the services delivered, by whom and
where in the community these services are provided. In
home-based delivery, clients receive their adherence sup-
port and pre-packed medications once every 3 m in their
homes by a trained lay worker [33, 34]. CBDPs allow pa-
tients to pick up their drug refills at a designated place
in the community [26, 27, 35, 36].
These models of care are best directed towards stable
adult patients, defined as those with suppressed HIV
viral loads on ART for more than 6 m. It allows them to
receive treatment and sometimes medical care within
their communities with ongoing adherence support
where needed, and may sometimes involve community
health workers (CHWs) dispensing pre-packedART, thus
reducing the frequency of clinic visits.
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Ideal nHFBC models of ART delivery must be sustain-
able and safe. They must confer similar successful clin-
ical outcomes in order to effectively contribute to the
decrease of HIV transmission and extension of life ex-
pectancy. Feasibility of these models need to be strin-
gently evaluated and compared with concurrent HFBC
in order to determine the safe sustainable delivery of
ART to UNAIDS targets. Several systematic reviews
published recently have shown that community pro-
grams increase both affordability and accessibility to
ART [24] and have shown that there are no significant
differences in optimal ART adherence, virological sup-
pression (VS), all-cause mortality and loss-to follow-up
(LTFU) between patients assigned to nHFBC and HFBC
[23, 37]. This review looks at programmatic data and tri-
als from 2010 onwards in order to provide an update on
large amounts of recently published data, as several
models have been rolled out providing more data on
clinical outcomes.
We undertook a review of published literature com-
paring HFBC with nHFBC models of ART delivery in
terms of health outcomes; viral suppression, loss to
follow-up, retention and mortality among PLHIV. We
included all descriptions of novel programmatic delivery
of ART in nHFBC settings, and compared where avail-
able specific outcomes between HFBC and nHFBC, in-
cluding VS, mortality, retention and LTFU.
Methods
Search strategy
A systematic electronic search of peer-reviewed litera-
ture was conducted most recently on the 21 August
2019 in the following databases: Medline, Embase and
Global Health. The search strategy was created with the
support of a medical librarian; key terms were identified
to combine ART AND nHFBC AND SSA. The search
strategy is outlined in full in Additional file 1: Appendix
1. The review was prospectively registered with online
database PROSPERO (ID=CRD42018088194). In
addition to the databases, two key UNAIDS reports and
all WHO guidelines, and their references, from 2010 on-
wards were reviewed.
Eligibility criteria
Articles were considered for inclusion if they described
the effectiveness of one of four nHFBC methods of deliv-
ery of ART in sub-Saharan African settings: adherence
clubs, CAGs, CBDPs and home-based delivery. Adher-
ence clubs were included irrespective of whether they
were physically located within the healthcare facility or
in the community as they are run independently and are
considered novel care pathways outside the routine
HFBC pathway. Appointment spacing, and fast track re-
fills that take place within the facility were excluded as
this was considered to be part of standard HFBC path-
way. Studies had to measure a clinical outcome, either;
retention in care, LTFU in accordance with WHO and
national guidelines definitions, transfer to alternative
care, viral load (VL), viral suppression (VS), CD4 count
or mortality. The definition of LTFU varied by study and
year, but papers were considered eligible if they defined
LTFU in accordance with standard WHO and guideline
practices [38]. While some studies reported patient out-
comes within the LTFU cohort, such as death or transfer
to other services, this was not essential for inclusion.
The definitions of viral suppression were varied between
studies as laboratory assays changed, but for this analysis
we included all papers that reported to < 1000 copies
HIV RNA/mL.
For inclusion, studies were not required to have a
comparator current standard of care control group. It
was not necessary for studies to be delivering ART in
isolation of other interventions, such as counselling.
There was no restriction on study population age, his-
tory of infection or line of ART.
Original research articles were included, and system-
atic reviews were excluded. Where data from the same
cohort was published multiple times, the most recently
available publication was included. The search was con-
ducted in English only due to available expertise, time
and budgetary restrictions. A publication date limit of
1st January 2010 until 31st August 2019 was applied to
the searches in all databases as the aim was to review
the current published literature and update previously
published review articles [24].
Data extraction and quality appraisal
All database search results were imported into EndNote
software (EndNote X8.2) for duplicate removal, and then
into Covidence systematic review software, which was
used for screening [39]. The screening of titles and ab-
stracts and the full text reviews of eligible articles were
done in duplicate by two independent reviewers (GZ,
ML). All conflicts were resolved through discussion be-
tween both reviewers, and a third reviewer (SF). Where
full texts of abstracts were not available, these were
accessed via the British Library. Additional articles were
identified by examining references of articles included
for full text review (Fig. 1). Articles considered eligible
for inclusion were read in full by GZ & ML, and ap-
proved by reviewer SF.
Data was extracted in duplicate by two reviewers (GZ,
ML), including: first author, year of publication, country
of origin, study design, sample size, the community
model used to deliver ART, outcomes, length of follow
up and who was responsible for ART provision. All dis-
crepancies in data extracted were solved through discus-
sion between both reviewers. Results of this data
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extraction were summarized in Table 1. Quality analysis
was done by reviewers GZ and ML using the Cochrane
tool for risk of bias for all randomised control trials
(RCTs) and using the Newcastle-Ottawa scale [58, 59]
for cohort studies, which can be found summarised in
Appendices 2 and 3.
Quantitative and qualitative analysis
Results were extracted for VS (thresholds defined in the
articles ranged from ≤1000–400 copies HIV RNA/mL),
mortality and LTFU/retention in care. Studies with vari-
able definitions of VS were still considered eligible for
quantitative comparison. Pooled estimates of the com-
parison between nHFBC and HFBC were calculated for
both VS and mortality using random-effects meta-
analysis. When comparing VS, the pooled risk difference
was the reported statistic, and for mortality the pooled
hazard ratio was reported. Due to the large variations in
the definitions of LTFU and retention in care between
papers, only a descriptive analysis was carried out in ac-
cordance with the Synthesis without meta-analysis
(SWiM) in systematic reviews: reporting guideline [60].
For quality assessment, RCTs were risk assessed using
the Cochrane Risk of Bias tool [59] which can be found
in full in Additional file 2: Appendix 2. Quality assess-
ment of cohort studies was done using the Newcastle-
Ottawa Scale (Additional file 3: Appendix 3) [58].
Results
Our search identified 3082 non-duplicate records, of
which 2889 were excluded after abstract and title screen-
ing against our search criteria. One hundred ninety-
three records were eligible for full text screening, of
which 21 published papers were eligible for inclusion in
our analysis (Fig. 1).
Of the 21 articles included, results were presented
from a total of six randomized control trials (RCTs) [37,
40–44], 15 observational cohort studies [32, 36, 37, 45–
56] and one cross-sectional study [57] (one article pre-
sented the results from both an RCT and a cohort
study). These studies were conducted in SSA, including:
South Africa, Uganda, Tanzania, Mozambique, Kenya,
Zimbabwe, Eswatini and Democratic republic of Congo.
The number of participants included in the studies
ranged from 129 to 129,936, and the design and meth-
odology of the included studies are detailed in Table 1.
Our included articles represented nHFBC models that
provided service delivery either as individual or group
Fig. 1 PRISMA flowchart of search strategy
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Table 1 Characteristics of the studies and their Design, nHFBC model and key findings






Outcomes and key findings
RANDOMIZED CONTROL TRIALS







18 months Viral Suppression – comparable 12 months viral suppression
between the intervention (80%) and control (79.6%) arms (aRD:
3.8%; 95% CI: −6.9 to14.4%).
Retention – AC’s had a higher 1-year retention (89.5% vs
81.6%, aRD:8.3%; 95% CI: 1.1 to 15.6%)
Hanrahan 2019
[40]






N = 775 24 months Loss from the club – proportion of patients who dropped out
of clubs in both community and facility clubs or were
transitioned to standard of care. Overall, 47% [95%CI 44–51%]
of patients were returned to health care facility. Among
community-based club participants, the cumulative proportion
lost from club-based care was 52% (95% CI: 47–57%), compared
to 43% (95% CI: 38–48%,
p = 0.002) among clinic-based club participants.
Virological failure - Documented viral rebound was higher
among participants assigned to facility-based clubs (21, 95% CI
13–27%) than those assigned to community-clubs (13, 95% CI
8–18%, p = 0.051). But this was not significant.
All-cause mortality – no mortality observed in both arms
Loss from ART care -during follow up, 77 (10%) overall. No
significance between the two arms. Among community club
participants, the proportion lost from any ART care was 12%
(95% CI 9–16%), compared to 7% (95% CI 5–10%, p = 0.024)
among facility- club participants, corresponding to a difference
of 5% (95% CI 1–9%, p = 0.018). In a univariate Cox
proportional hazards model, the risk of loss to any ART care
was non-significantly increased among participants assigned to
community clubs as compared with those assigned to facility
clubs (HR 1.69, 95% CI 0.98–2.91, p = 0.057).
Geldsetzer 2018
[41]







326 days Virological failure – 10.9% (95/872) in the control arm and
9.7% (91/943) in the intervention arm were failing at the end of
the study period.
Risk ratio demonstrated non-inferiority of the HBC to HCF (RR
0.89 [1-sided 95% CI 0.00–1.18])
Lost to follow-up – 18.9% in HBD versus 13.6% in HCF. No P
value or CI reported.











28 months Home delivery of ART and support leads to similar survival
rates as clinic-based care.
Mortality – One hundred and ninety-seven participants died
over a median follow-up time of 28 months (IQR 15–35) giving
an overall mortality rate of 6.36 deaths per 100 person-years
[95% confidence interval (CI) 5.53–7.32].
110 (25%) deaths in participants with baseline CD4 < 50 cells
and 87 (9%) in those with higher baseline CD4.Among
participants with baseline CD4+ count < 50cells/μl, mortality
rates were similar for the home and facility-based arms; ad-
justed mortality rate ratio 0.80 [95% confidence interval (CI)
0.53–1.18] compared with 1.22 (95% CI 0.78–1.89) for those
who presented with higher CD4+ cell count.
In CD4 counts < 50 cells – crude mortality RR 0.81 and In CD4
counts higher - crude mortality RR 0.55
Lost to follow up – 1.8% among those with CD4 < 50 and
2.6% among those with CD4 at least 50.






42 months Mortality – in the facility there were 117 deaths (mortality rate
6.3 per 100 persons per yrs.) whereas in HBD, 80 deaths
(mortality rate 6.5 per 100 person yrs.). The one, two and three
year survival probabilities (95% CI) were 0.89 (0.87–0.91), 0.86
(0.84–0.88) and 0.85 (0.83–0.87) respectively






28 months Home delivery of ART and support resulted in similar clinical
outcomes as clinic care but with half the number of clinic
visits. Task-shifting and mobile technologies can deliver safe
and effective community-based care to PLHIV.
LTFU – 4.5% in the HCF and 5.2% in Home delivery [95% CI:
0.24 to 3.03; p = 1.0]
Mortality – 0 in both arms
Viral rebound – no significant difference between the two
groups (10.5% in HBD and 13.5% in HCF, 95%CI: 0.54 to 3.31,
p = 0.65)
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Table 1 Characteristics of the studies and their Design, nHFBC model and key findings (Continued)






Outcomes and key findings
OBSERVATIONAL COHORT STUDIES



















6 months Retention in the CBDP – 82.8% vs 82.1% in the HCF at 6
months





(CAGs) 2. Facility Based
clubs
3. Treatment outreach







12 months Retention in the models – The overall care model retention
was 90.9 and 82.2% at 6 and 12 months. Retention in the care
models differed significantly by model type, being lowest in
CAGs at all time points (p < 0.001). Only 70.4% of patients were
retained in CAGs at 12 months compared with 86.3% in
comprehensive outreach and 90.4% in clubs. Retention in care
model was significantly higher in eligible patients compared
with non-eligible patients (85.0 and 76.4% at 12 months, p =
0.017.
Retention to ART – over 90% from all three models and no
difference noted (p = 0.52).Patients in CAGs had a higher risk of
disengaging from the care model (aHR 3.15, 95%CI: 2.01–4.95,
P < 0.001) compared with treatment clubs.
Note: disengagement defined as LTFU, Death, return to clinical
care)












Viral suppression - overall no difference in viral suppression
between the two groups.
86% of women remained in the evaluation through 6
months postpartum; in this group, there were no
differences in VL < 1000 copies/mL at six months
postpartum between women choosing HCFs (88%) vs.
adherence clubs (92%; p = 0.483.





No comparator N = 2259 24 months Attrition increased steadily after decentralizing services such as
drug pick up points.
Low attrition throughout follow-up
LTFU – 9.0% at 24 months
Mortality – 0.3% at 24 months
overall attrition was 5.66/100 person years (95% CI: 4.97 to 6.45)
Tsondai 2017
[49]
South Africa Adherence clubs No comparator N = 3216 24 months Stable patients on ART can safely be offered differentiated care
as they overall had good outcomes. Adherence clubs scaled up
at large scale had had high levels of retention and viral
suppression.
Retention – Retention was 95.2% (95% CI: 94.0–96.4) at 12
months and 89.3% (95% CI: 87.1–91.4) at 24 months after AC
enrolment.
Viral suppression - Of the 88.1% who had a viral load
assessment, 97.2% (95%CI, 96.5–97.8) were virally suppressed <
400 copies/ml
LTFU – 4.2% (135). Cumulative incidence of LTFU was 2.6%
(95% CI, 2.1–3.2) at 12 months, rising to 6.9% (95%CI, 5.7 to 8.1)
at 24 months after AC enrolment.
Mortality – 0.1% (95% CI, − 0.01 to 0.2) at 12 months and 0.2%











24 months LTFU – overall 12% [11.2% in HCF and 0.8% in CAGs]. CAG
members had a greater than fivefold reduction in risk of dying
or being LTFU (adjusted HR: 0.18, 95% CI 0.11 to 0.29).
Retention - 12-month and 24-month retention in care from
the time of eligibility were 89.5 and 82.3% respectively among
patients in individual care and 99.1 and 97.5% among those in
CAGs (p < 0.0001).










4 years Mortality – similar rates in both groups [0.3% among CASG at
2 yrs. and 1.4% at 4 yrs.]
CASG patients were associated with a 35% lower LTFU rates
[AHR 0.65; 95% CI:0.46, 0.91] but similar mortality.
Grimsrud 2016
[52]






12 months Viral suppression – high rates of VLS among those who had a
VL result, but no comparison made between the two cohorts.
LTFU – clubs were associated with a decreases risk of LTFU
compared to facility in all crude and adjusted models. Clubs
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models outside the healthcare facility including facility
or adherence clubs, home-based delivery, community
adherence groups or distribution points and outreach
ART delivery (Table 1). ART delivery was done by a
range of community healthcare workers, volunteers and
nurses.
The six randomised control trials were appraised using
the Cochrane tool for risk of bias. Sequence generation
Table 1 Characteristics of the studies and their Design, nHFBC model and key findings (Continued)






Outcomes and key findings
6037 were associated with a 67% reduction in LTFU compared with












5 years Overall retention rates were above 80% in both HCF and CBDP
Retention rates – 83.9% in the facility and 82.9% retained in












12 months LTFU – LTFU among CASG and non-CASG members was 7.2
and 15.9%, respectively. Compared with CASG participants,
non-CASG participants had significantly higher LTFU (hazard ra-
tio [HR]: 2.36; 95% confidence interval [CI]: 1.54–3.17; p = .04]
Mortality -no significant mortality differences between CASG
and non-CASG members (1.4% vs 1.2%) (HR:0.98; 95%CI, 0.14 to








5 years Community-based ART distribution systems are capable of
overcoming barriers to ART retention and result in good rates
of virologic suppression.
Viral suppression- of the 870 patients who had a VL
measured, 87% were suppressed
Mortality- mortality rate was low (3.22 per 100 person-years)
LTFU- 1.59 per 100 person-years
Retention- more than 69% of patients who initiated ART from








4 years Long-term retention in CAG was exceptionally high [91.8% at 4
years of follow-up (95% CI, 90.1 to 93.2)].
LTFU – event rate was 0.1% per 100-person yrs.
Mortality – event rate was 2.1 per 100-person yrs.
Retention among CAG members at 1 year on ARTwas 97.7%
(95% CI 97.4–98.2); at 2 years, 96.0% (95% CI 95.3–96.6); at 3
years, 93.4% (95% CI 92.3–94.3); and at 4 years, 91.8% (95% CI
90.1–93.2).
Overall, the attrition rate was 2.2 per 100 person-years among
the 5729 adult members.

















3 years Outcomes less frequent in patients participating in the clubs.
Viral rebound – 214 patients had viral failure at study end in
the HCF (90.4 event rates per 1000 person yrs. [95%CI: 79.1–
103.4). In the clubs 14 had viral rebound 31.8 event rates per
1000 person yrs.
Retention - 97% of club patients remained in care compared
with 85% of other patients. In adjusted analyses club
participation reduced loss-to-care by 57% (hazard ratio [HR]
0.43, 95% CI = 0.21–0.91).
Mortality + LTFU - 12.8% of patients were LTF or had died (323
LTF and 40 deaths).
Both outcomes were less frequent for patients participating in
the clubs (29.8 vs 116.8 per 1000 person-yrs. for LTFU/death,
crude rate ratio [RR = 0.25, 95% CI 0.14–0.41]








24 months ART outcomes such as viral suppression in community models
were equivalent to those receiving care in the facility.
Viral suppression – patients in the home delivery model were
2.47 times more likely to achieve viral suppression compared to
those in the facility based [95% CI for OR 1.02–6.04 p = 0.046].
Mortality – 32(17%) in Home delivery vs 23 (12%) in HCF. This
had limitations as the LTFU in both groups includes unknown
number of deaths. Crude mortality was higher in the HBD
cohort compared to the HCF cohort, though this difference
was not statistically significant (17.3% vs. 11.5%, p = 0.10).




Zimbabwe Outreach ART delivery No comparator N = 143 18 months Viral suppression- over the course of the study period, 94%
were virally suppressed
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and allocation concealment were well conducted, and
risk of bias was low amongst the studies. Blinding of
participants and personnel was not possible in any of the
studies due to the nature of the intervention, but there
was variability amongst blinding of outcome assessors as
in some cases the assessors were also involved in project
management. The data collected however were generally
objective measures obtained from medical records,
which is at minimal risk of bias, even for assessors who
were informed of patient allocation. Not all RCTs had
published study protocols, which increases the risk of se-
lective outcome reporting, but all did report numbers of
attrition and mortality, minimising risk from incomplete
outcome data.
Virological suppression (VS) and viral load (VL)
From our included studies, 10 out of 21 reported VS or
HIV viral load rebound as an outcome measure. Of
these, three articles [36, 49, 57] did not compare to a
facility-based cohort and were therefore excluded from
the pooled analysis. Three articles [37, 41, 44] were
RCTs that compared outcomes to a facility-based co-
hort, one of which [37] included results from two separ-
ate RCTs published in the same article. The remaining
four studies were all observational cohort studies [47,
52, 55, 56] comparing VS among participants receiving
community-based care with those receiving facility-
based care. The pooled risk difference of virological sup-
pression amongst RCTs are shown in Fig. 2, and includ-
ing the observational studies are shown in Additional
file 4: Appendix 4. There was a remarkably consistent ef-
fect (I2 = 0.04%) found across the four randomized trials,
very marginally in favour of community care, with an
overall estimated risk difference of 1% [95%CI -1, 4%).
There was no statistically significant evidence (p = 0.24)
of a difference in viral suppression between the two
groups. The definition of viral suppression varied be-
tween studies, with Geldsetzer et al. using < 1000 copies/
ml, Fox at al using < 400 copies/ml, and Selke not
defining it. The viral load or suppression reported at
baseline in these RCTs also varied. Geldsetzer reported
the percentage of people with VL < 1000 copies/ml or
CD4 < 350 cells/μl (which was 17.4% in control and 15.4%
in intervention group),. Fox reported the median viral load
(copies/ml) and interquartile range. For the adherence
club (AC) control and intervention groups, these were 50
(20–124) for both and in the Decentralized Medication
Delivery (DMD) control and intervention groups these
were 42 (20–100) and 124 (35–124) respectively. Selke re-
ported the proportion with detectable viral load at base-
line, which was 8.5% in the intervention and 12.6 in the
control group. These were all studies assessed as high
quality, and apart from not being blinded, all had an over-
all low risk of bias. Three of the four observational studies
showed results broadly consistent with the randomised
trial results (although slightly more favourable towards
nHFBC, with risk differences ranging from 4 to 6%). One
study by Grimsrud et al. had results showing much greater
viral suppression in nHFBC (estimated risk difference of
39%), although in that paper the patients receiving nHFBC
were those who were classed as “stable on ART” and the
comparison group were not (adjusted results for VS were
not presented in the paper) [52].
Mortality
Nine papers were identified that reported mortality, four
of which were RCTs. Only two RCTs [42, 43] did a for-
mal comparison between trial arms on mortality. The
two RCTs included in the pooled analysis were rated as
fair quality, and reported the results stratified by
whether baseline CD4 count was less than or greater
than 50, increasing the accuracy of the intervention
comparison. The other two RCTs reporting extremely
low rates of mortality (Selke et al. reported no deaths in
HFBC and one in nHFBC and Geldsetzer et al. reported
two in HFBC and one in nHFBC). Of the five observa-
tional cohort studies, four reported a formal comparison
of mortality. The hazard ratios across all studies ranged
Fig. 2 Forest plot for estimated pooled risk difference comparing viral suppression among those receiving health facility-based care (HFBC) and
non-health facility-based care (nHFBC), including results only from randomized controlled trials. Legend to the figure: Dashed line represents zero
risk difference. VS (virally suppressed)
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from 0.8 up to 1.2, but with all confidence intervals
crossing the null of HR = 1 (Fig. 3). This resulted in a
pooled estimate equal to 1.01 (95% CI 0.88–1.16), pro-
viding no evidence (p = 0.92) of a difference in the mor-
tality rate among those not in facility-based care
compared to those in facility-based care.
Due to the large amount of heterogeneity, results were
described for LTFU and retention in care without formal
methods of statistical comparison. Instead, data was tab-
ulated comparing reported outcomes. A page referencing
guide for the SWiM guideline for these outcomes can be
found in Additional file 5: Appendix 5.
Loss to follow-up
A total of 15 studies reported LTFU as an outcome, of
which four were from RCTs and 11 from observational
cohort studies and are summarized in Table 1 and Add-
itional file 6: Appendix 6. In most studies LTFU was de-
fined as no longer having contact with the care services,
but there was a large degree of variability in the time
frame. This commonly ranged from 60 days to 6months,
however multiple studies defined LTFU as no visit or
contact with the service during the study period, which
was up to 5 y. Additionally, there were varying degrees
of investigation into outcomes of the LTFU populations,
with some studies documenting mortality and transfer
to alternative services, and some not documenting any.
In the studies included, there were four RCTs that in-
cluded LTFU as an outcome where LTFU was defined as
outlined in Additional file 6: Appendix 6 and varied be-
tween studies [34, 40, 42, 44]. A cluster RCT undertaken
in South Africa comparing adherence clubs with
healthcare facility clubs over a 24months period showed
105 patients were LTFU with no significant difference be-
tween the two study arms [40]. Their definition varied
from those used in other studies as it was a measure of
loss from their intervention, which goes beyond missing
visits, but also includes patients who developed any of the
exclusion criteria, such as comorbidity or viral rebound. A
RCT in Tanzania [41] compared home delivery to HFBC,
and defined LTFU as not having a VL measurement after
enrolment into the model of care over the entirety of the
12-month study period. They demonstrated non-
inferiority in the rates of LTFU. In the other two rando-
mised trials by Selke et al. and Woodd et al., LTFU was
defined as not having had contact with the care services
during the study period, which was 28months in both
studies. Selke et al. [44] compared home delivery model to
healthcare facility in Kenya and showed comparable LTFU
outcomes (4.5% in HFBC versus 5.2% in home delivery)
and similarly, Wood et al. compared home delivery to
HFBC in Uganda and demonstrated similar rates of LTFU,
which were 2.36% in the facility and 2.33% in the commu-
nity [42].
Eleven observational studies reported LTFU with vary-
ing definitions. Six of these studies did a comparison be-
tween nHFBC and HFBC and showed nHFBC had
comparable or better LTFU outcomes compared to
HFBC [45, 50–52, 54, 55] (Additional file 6: Appendix 6:
Table 4). Among these, LTFU was defined as being late
for their scheduled pharmacy pick-up date by either 60,
90 or 180 days late with the exception of Tun et al. who
defined LTFU as combined mortality, transfer out and
withdrawal [45]. Grimsrud et al. showed community
Fig. 3 Forest plot for estimated pooled hazard ratio comparing mortality among those receiving health facility-based care (HFBC) and non-health
facility based care (nHFBC). Legend to the figure: dashed line represents hazard ratio of 1. *Wood (A) is among participants with a baseline CD4
count < 50, while Woodd (B) is among participants with a CD4 count of 50 +
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adherence clubs were associated with a reduction in the
risk of LTFU compared with the clinic with a two-third
reduction in the hazard of LTFU [52] (Additional file 6:
Appendix 6). Luque-Fernandez et al. compared adher-
ence clubs to healthcare facility and demonstrated that a
combined outcome of time to either death or LTFU was
less frequent in club participation than in the facility
(crude RR 0.25 95%CI: 0.14, 0.41) [55]. Similarly, in
Mozambique, patients who participated in community
adherence support groups were associated with a lower
LTFU rates as compared to those who did not partici-
pate in these groups. Auld et al. showed participating in
CAGs was associated with a 35% lower LTFU rates
(AHR 0.65; 95%CI: 0.46, 0.91) [51]. Another study com-
paring CAG to non-CAG showed higher LTFU rates
amongst non-CAG members (HR 2.36 95%ci: 1.54, 3.17)
[54]. In the same country, a comparison between CAGs
and HFBC showed that CAG members had a greater
than 5-fold reduction in the risk of combined LTFU and
mortality (adjusted HR 0.18 95%CI: 0.11, 0.29) [50]. A
total of five studies had no comparison to HFBC [32, 36,
46, 48, 49] and despite varying definitions of LTFU, a
study in South Africa showed a cumulative incidence of
LTFU at 2.6 and 12.2% at 12 and 24months respectively
[48, 49] (Additional file 6: Appendix 6: Table 5).
The definition of LTFU varied amongst included stud-
ies, including a missed scheduled visit, being late for
drug pick-ups or withdrawal from a model, which could
include death or patients transition to alternative health
care facility. For studies that defined LTFU as having
missed a scheduled visit or model withdrawal, only three
indicated patients transition to HFBC [40, 41, 45].
Retention
A total of 13 studies in our review, two of which were
published in the same paper [37], reported retention as
an outcome, nine of which provided a comparison to
health facility based care (Additional file 6: Appendix 6
Table 4). Three RCTs compared retention between
nHFBC and HFBC [37, 41, 44], which showed that the
community models had comparable rates to those in the
facility. Fox et al. defined retention as those not LTFU,
died or transferred to alternative care, and reported
81.6% participants retained in facility and 89.5% partici-
pants retained in the community with a risk difference
of 7.8% [37]. Selke et al. defined it as those still in care
at the end of the follow up period, reporting rates of
91.1% in facility compared to 90.6% in the community
[44]. Similarly, Geldsetzer et al. defined attrition as those
no longer in care, the inverse rates of which are reported
as retention of 86.4% in the facility and 81.1% in the
community [41].
Equally, most observational studies demonstrated simi-
lar retention outcomes between nHFBC and HFBC [45,
53, 56] or better retention outcomes in nHFBC [50, 54].
Only one study showed better HFBC retention rates
[37]. Definitions of retention in care used were similar
across all studies, however there was large variation in
follow up period, ranging from six months to five years.
Among the four studies that did not provide a compari-
son to HFBC, retention rates for nHFBC generally
exceeded 90%, including a study with follow up of four
years. A study from 2015 by Okoboi et al. was the excep-
tion, reporting a retention rate of 69% in patients on
treatment for more than five years [36].
Discussion
We reviewed articles describing the current evidence of
community ART programs taking place in SSA between
2010 and 2019 on the following key outcomes; Viral load
suppression, mortality, LTFU and retention. From our
review, all the articles that described nHFBC ART pro-
grams found evidence that decentralizing HIV services
into the community for PLHIV has promising outcomes
and is a safe alternative to facility based care programs
in resource limited high burden HIV settings for stable
PLHIV on ART. Adherence clubs that were physically
located within the health-care facility were also consid-
ered as nHFBC as they ran independently and thus con-
sidered as outside the standard HCF provision. The
studies suggest that levels of VS and mortality are simi-
lar in both nHFBC and HFBC groups. Similarly, with
regards to LTFU and retention, articles included in our
review showed comparable or slightly better LTFU and
retention outcomes amongst nHFBC models when com-
pared to HFBC. However, whilst we identified 21 articles
that described one or more outcomes of nHFBC models
in SSA countries, only two-thirds of the articles com-
pared these models to the HFBC, limiting the strength
of conclusions that can be drawn.
In all included articles, the primary clinical care pro-
vider for these nHFBC models was poorly described, but
provision of the core packages such as ART dispensa-
tion, adherence support and referrals of sick patients to
the clinics was often shared by community or trained lay
workers. nHFBC models have shown that decentralizing
HIV services into the community may potentially over-
come major structural and financial barriers faced by
PLHIV to ART initiation and retention [27]. These
models are capable of achieving a range of potential add-
itional benefits to healthcare providers and PLHIV on
ART, including patient satisfaction, reduced costs, con-
venient and efficient service delivery and better clinical
outcomes and promote healthy behaviors such as de-
crease alcohol abuse [23]. As the numbers of PLHIV
accessing treatment increases following the 2015 WHO
ART guidelines [9], nHFBC models have shown the po-
tential to be able to deliver a package of essential ART
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services beyond the clinic, freeing up the capacity within
the HFBC workforce to be able to focus on more com-
plex cases [24].
Our findings suggest that nHFBC programs can
achieve favorable outcomes for stable PLHIV on ART in
resource limited settings, which is in line with a previ-
ously published systematic review by Decroo et al. that
looked at community-based intervention programs [24].
This review has updated and summarized the evidence
that has been published since Decroo et al’s review in
2013, and proposes that community-based intervention
programs can make treatment readily accessible and af-
fordable as well as help support adherence and sustain
retention of patients on ART over the long term [24]. In
Uganda, Kenya and Tanzania, lay workers or community
health workers delivered ART to patients homes [41, 44,
61] whereas in Tete, Mozambique, CAGs were used to
deliver ART within the community [50]. Similarly, in
South Africa, adherence clubs piloted by MSF equally
showed promising results [55].
With respect to other relevant outcomes, studies com-
paring CD4 count outcomes between HFBC and nHFBC
models showed patients in nHFBC models can achieve
similar outcomes in terms of CD4 gains [44, 52]. Decroo
et al. also included studies analyzing costs of the inter-
ventions, and found that provider costs were either simi-
lar or lower in nHFBC models, and considerably more
cost-effective for patients [24]. Our review did not in-
clude cost-analysis as there have been very few studies
that have informed on the costs or cost-effectiveness of
these nHFBC models. Studies that have reported on
costs have found that provider outcomes were similar
for HFBC and nHFBC [62, 63]. One study found that
community-based intervention programs were much
more cost-effective than estimates for facility based care
[64]. However, a recent study in Tanzania showed that
although patient satisfaction with a home-based program
was high and was likely to save patients substantial
amount of time, other envisaged benefits of decongest-
ing the healthcare facility and reductions in patients’
health expenditures were minimal [41]. Clearly more re-
search using economic outcomes in different contexts to
compare the costs, effectiveness and sustainability of the
models are needed. Available data suggests that these
models, even if equivalent or significantly non-inferior to
the HFBC, may be more cost-effective. Patient transpor-
tation costs and use of personnel, operational and utility
costs are likely to be lower. This in addition to improved
retention rates are more likely to make nHFBC models
more cost-effective and sustainable in the long run [23].
At the time of writing, Long et al. published a rapid re-
view of differentiated service delivery models for ART in
SSA and noted despite the widespread expectations that
these models will be cost-saving, they found little data to
support this contention [65]. When evaluating program-
matic costs of such nHCFB models of ART delivery, an
additional cost that is difficult to measure is the poten-
tial costs associated with onward HIV transmission
amongst those who interrupt ART with consequent viral
rebound.
nHFBC models also have the potential to have an im-
pact on the relationship between healthcare providers
and patients and can thus strengthen social and peer
support [66]. These models have the opportunity to
transform the current siloes to a more integrated ap-
proach that will enable HIV care to be combined with
care for other conditions, including non-communicable
diseases that are becoming more prevalent in resource
limited settings [23].
Our study had several limitations and despite search-
ing several databases, yielded a small number of studies
that looked at ART delivery for final inclusion. We also
noted there is paucity of data from other regions in
Africa such as West and Central Africa where the HIV
burden is high. nHFBC delivery models are recent strat-
egies and at present resource constraints make this a
challenge in many sub-Saharan African settings. The
heterogeneity of these nHFBC models in our review
ranged from the diversity of the models, be definition
and the evaluation methods. Of the 21 articles that were
included for inclusion only 15 articles compared out-
comes with HFBC, making data available for analysis
limited, and its inclusion in the meta-analysis imperfect.
Instead of comparing outcomes from every individual
nHFBC model to HFBC model separately, the results
were pooled, and all community-based programs were
evaluated against the standard of care causing clinical
heterogeneity. Another limitations in this review include
the heterogeneity of the articles that met our inclusion
criteria which could have manifested in several ways.
Our topic was diverse and the methods of evaluating
nHFBC outcomes ranged from facility-site, observational
cohorts to randomized trials. With regards to studies
reporting on mortality in our review, two observational
studies did a comparison between patients who chose
nHFBC or not [51, 54] and one study did a comparison
in two different settings [56] which could have resulted
in bias due to the fact that whether participants received
nHFBC or HFBC was not allocated at random. The re-
ported effect estimates were adjusted for potential con-
founders to mitigate this. Although some residual
confounding may remain, the effect observed in the ob-
servational cohorts is consistent with that seen in the
randomized studies. Assessing outcomes such as LTFU
in our review was also a limitation. The lack of a stand-
ard definition for LTFU across studies included in our
review made it difficult to assess the trends and differ-
ences in LFTU to accurately measure the effectiveness of
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these programs and obstructed comparibility between
HFBC and nHFBC models. LTFU is an important indi-
cator to accurately measure effectiveness of ART pro-
grams and therefore there is need for a standard
definition in order to understand the changes within and
the differences between ART programs especially in set-
tings where ascertainment of mortality is weak. Lastly,
unsuccessful pilot studies are less likely to be published,
introducing publication bias. Studies included in this re-
view introduce bias in measured outcomes in that those
included with available data may differ in terms of stabil-
ity, ability to access care and treatment or being able to
make a choice. The value of such nHFBC models for
people currently not retained in care is not included in
this systematic review. Other limitations include the di-
versity of the set-up of these nHFBC models and the
study design, resulting in observation bias, and con-
founding bias when a comparison was made. In this re-
view, stable patients were offered the chance or were
able to choose themselves and both avenues introduce
significant selection bias, as both these groups are likely
to contain individuals more dedicated to their health,
evident from their superior clinical outcomes or willing-
ness to participate actively in their care.
Although our findings have shown that nHFBC
models can complement HFBC service delivery with
regards to clinical outcomes and enhance patients ability
to manage HIV, there is need for more in depth infor-
mation on patients acceptability towards these models of
care as well as the negative and positive effects related to
stigma and ART delivery in the communities [35].
All the articles in our review, with exception of one
[42], focused on stable adult PLHIV on ART, which typ-
ically included being on ART for more than 6–12
months and either virally suppressed or immunologically
stable. However, there is a need to understand the im-
pact of nHFBC models on key populations who are fre-
quently excluded, such as youth and men who have sex
with men, who may benefit the most as they may avoid
clinics for other reasons such as domestic violence.
There is no data regarding nHFBC models towards key
populations and further pilot studies on nHFBC models
should be targeted towards key populations to determine
the feasibility and key clinical outcomes. In additon to
the models included in this review, there is a growing
trend towards supporting ART distribution from drop-in
centres, and therefore a need to assess their effective-
ness. However, at the time of evalaution, there were no
RCTs that included this approach to explore their out-
comes. There is currently scarce or no data regarding
patient satisfaction and improvement in quality of life
from these models and therefore further research is
needed to determine patient satisfaction and quality of
life from these models. Feasibility of implementing these
models equally need to be explored as most of these
models are implemented by in-country implementing
partners with additional funding and resources, and need
to understand how these models can be placed into the
context of existing healthcare sytem without external
funding.
Conclusions
This systematic review further demonstrates non-
inferiority of nHFBC amongst stable PLWH on ART in
high HIV burden, resource limited settings in sub-
Saharan Africa for key outcome measures of VS, death
or LTFU compared with current standard HFBC
models.
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